Evolus Inc. (EOLS)
NASDAQ: EOLSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
EOLS stock chart
Technical analysisKey statistics
All statistics- Market cap
- $431.55M
- Forward P/E
- 22.68
- EPS (TTM)
- -$0.48
- Dividend yield
- None
- 52-week range
- 3.86 – 9.31
- Day range
- 6.50 – 7.19
- Volume / Avg
- 813.65K / 925.77K
- Beta
- —
- Shares outstanding
- 66.19M
52-week range
EOLS stock today
On Nov 20, EOLS ended the session at $6.52, shedding $0.48 (6.86%), versus the S&P 500's 3.70% decline. Shares are 30.0% below their 52-week high of $9.31, set on Sep 4, 2026 and 68.9% above the 52-week low of $3.86, in the middle of the past year's range. EOLS is down 2.0% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 4.8%.
Evolus has posted a net loss over the last twelve months (EPS of -$0.48), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Evolus
Company profileEvolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. David Moatazedi
- Headquarters
- Newport Beach, CA
- Employees
- 365
- IPO year
- 2018
- Website
- evolus.com
Financial highlights
Full financialsIn fiscal 2025, Evolus generated $297.2 million in revenue, up 11.6% from fiscal 2024, its 7th consecutive year of revenue growth. Evolus reported a net loss of $51.6 million, compared with a loss of $50.4 million a year earlier. Gross margin was 66.3% (down from 68.5%) and operating margin -11.0%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $297.18M | $266.27M | $202.09M | $148.62M | $99.67M |
| Growth | +11.61% | +31.76% | +35.98% | +49.10% | +76.29% |
| Net income | $-51.64M | $-50.42M | $-61.69M | $-74.41M | $-46.81M |
| EPS (diluted) | $-0.80 | $-0.81 | $-1.08 | $-1.33 | $-0.94 |
Analyst forecast
ForecastConsensus (6 analysts)
strong_buy
Avg. price target
$15.40+136.20%
- Strong buy 1
- Buy 4
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 4, 2026
- EPS actual vs est.
- $-0.19 vs $-0.14
- Surprise
- -35.71%
EOLS news
All EOLS news- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Evolus, Inc. - EOLSPR Newswire
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Evolus, Inc. - EOLSPR Newswire
- Evolus (EOLS) Q3 2026 Earnings Call TranscriptNasdaq
- Evolus, Inc. Reports Third Quarter 2026 Global Net Revenue of $78.0 Million and Reaffirms Full-Year Revenue GuidanceNasdaqEOLS, UHAL.B
- Evolus Reports Third Quarter 2026 Financial Results with 13% Year-Over-Year Revenue Growth; Delivers Fourth Consecutive Quarter of Positive Adjusted EBITDA and Reaffirms Full-Year 2026 Financial OutlookBusiness Wire
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Evolus, Inc. - EOLSPR Newswire
- Evolus to Report Third Quarter Financial Results on November 4, 2026Business Wire
Evolus peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| INDPIndaptus Therapeutics Inc. | 2.82 | -9.90% | $433.16M | vs EOLS |
| AQSTAquestive Therapeutics Inc. | 3.46 | -6.61% | $434.88M | vs EOLS |
| ARVNArvinas Inc. | 6.46 | -4.15% | $423.03M | vs EOLS |
| PRTAProthena Corporation plc | 8.22 | -2.14% | $422.10M | vs EOLS |
| CAPRCapricor Therapeutics Inc. | 7.59 | +0.80% | $441.30M | vs EOLS |
| LYELLyell Immunopharma Inc. | 13.80 | +1.62% | $441.82M | vs EOLS |
| CTMXCytomX Therapeutics Inc. | 2.03 | -0.98% | $442.55M | vs EOLS |
| CRMDCorMedix Inc. | 5.27 | +3.74% | $419.16M | vs EOLS |
Indexes, lists and sector
Evolus stock FAQ
What is Evolus's stock price today?
EOLS last traded at $6.52 as of Nov 20, 4:00 PM EST, down 6.86% on the day. Prices are delayed at least 15 minutes.
Who is Evolus's CEO?
Mr. David Moatazedi is the chief executive officer of Evolus Inc., which has about 365 employees.
What is the EOLS 52-week high?
The 52-week high for EOLS is $9.31 and the 52-week low is $3.86. The stock is currently 30.0% below its high.